BofA raised the firm's price target on 10x Genomics to $30 from $21 and keeps a Neutral rating on the shares after the company unveiled Atera, a next generation spatial transcriptomics platform enabling in situ whole-transcriptome analysis at single-cell resolution. For now, the firm makes no changes to its revenue assumptions, but it applies a higher multiple, reflecting increased confidence in spatial-driven growth and long-term market expansion, the analyst tells investors.
